NASDAQ · HURA
Healthcare · Biotechnology
$2.03
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 9:34 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
HURA closed at $2.03 after 20 trading sessions, down 6.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.05 | $2.05 | $1.98 | $2.03 | 132.26K |
| Sep 14, 2026 | $2.05 | $2.16 | $2.05 | $2.05 | 167.35K |
| Sep 11, 2026 | $2.05 | $2.10 | $2.04 | $2.05 | 113.97K |
| Sep 10, 2026 | $2.01 | $2.06 | $1.98 | $2.03 | 286.25K |
| Sep 9, 2026 | $2.12 | $2.15 | $2.00 | $2.01 | 148.92K |
| Sep 8, 2026 | $2.15 | $2.18 | $2.05 | $2.12 | 314.94K |
| Sep 4, 2026 | $2.09 | $2.155 | $2.06 | $2.14 | 367.76K |
| Sep 3, 2026 | $2.13 | $2.13 | $2.0403 | $2.10 | 114.28K |
| Sep 2, 2026 | $2.03 | $2.09 | $2.005 | $2.09 | 139.14K |
| Sep 1, 2026 | $2.11 | $2.13 | $2.03 | $2.03 | 152.9K |
| Aug 31, 2026 | $2.12 | $2.23 | $2.075 | $2.13 | 233.42K |
| Aug 28, 2026 | $2.15 | $2.15 | $2.04 | $2.11 | 99.68K |
| Aug 27, 2026 | $2.14 | $2.15 | $2.10 | $2.13 | 102.18K |
| Aug 26, 2026 | $2.03 | $2.135 | $2.03 | $2.13 | 158.75K |
| Aug 25, 2026 | $2.14 | $2.19 | $2.03 | $2.04 | 241.42K |
| Aug 24, 2026 | $2.10 | $2.195 | $2.03 | $2.15 | 143.45K |
| Aug 21, 2026 | $2.26 | $2.26 | $1.99 | $2.00 | 384.98K |
| Aug 20, 2026 | $2.26 | $2.31 | $2.20 | $2.22 | 148.64K |
| Aug 19, 2026 | $2.17 | $2.31 | $2.16 | $2.28 | 158.28K |
| Aug 18, 2026 | $2.32 | $2.3789 | $2.145 | $2.16 | 304.14K |
The latest Smart Investors Daily articles mentioning HURA.
HURA research
Company profile and research snapshot.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Citizens | Market Outperform | — |
| Apr 27, 2026 | Citizens | Market Outperform | — |
| Feb 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2025 | Maxim Group | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.
SeekingAlpha · Aug 18, 2026
TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call August 18, 2026 9:00 AM EDTCompany ParticipantsJames Bianco - President, CEO & DirectorDan...
Benzinga · Aug 18, 2026
Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform and maintains $9 price target.
Yahoo · Aug 14, 2026
TuHURA Biosciences (NASDAQ:HURA) outlined plans for its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, highlighting an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HURA.
